Zuellig Pharma, a leading healthcare services provider in Asia, announces the appointment of John Graham as its new CEO. John will run the US$13 billion business and lead the team across 13 markets in Asia.
He joined Zuellig Pharma in 2018 to oversee the development and growth of Zuellig Pharma’s Commercial Solutions business, spearheading the growth of its marketing, sales, business development and regulatory services. He takes over the helm from former CEO John Davison who retired at the end of last month.
John has over three decades of industry experience in biotech, pharmaceuticals, strategy consulting and healthcare investment banking across Europe, Asia, Latin America and the United States. He previously held various senior global leadership positions at Aventis, Genzyme and Ernst & Young, as well as the role of CEO at Menarini Asia-Pacific based in Singapore, where he established the company’s Asia-Pacific commercial footprint.
John assumed his new role on 1 July this year and is based in Zuellig Pharma’s headquarters in Singapore.